Bausch & Lomb sale

Bausch & Lomb, the eye care company, has agreed to be sold to Canadian healthcare firm Valeant Pharmaceuticals in a deal valued at about US$8.7 billion (around $9 billion).

The total deal is about US$8.7 billion. Valeant will pay roughly US$4.5 billion to the investor group that owns Bausch & Lomb and will spend about US$4.2 billion to repay Bausch & Lomb's outstanding debt.

Bausch & Lomb was owned by an investor group led by private equity firm Warburg Pincus, which will receive roughly US$4.5 billion as part of the sale.

The buyer is Valeant Pharmaceuticals, a Canadian healthcare company that has agreed to acquire Bausch & Lomb for about US$8.7 billion.

Valeant's roughly US$8.7 billion outlay is split into about US$4.5 billion paid to the investor group that owned Bausch & Lomb and about US$4.2 billion used to repay Bausch & Lomb's debt.

Bausch & Lomb is described in the report as an eye care company.

By buying Bausch & Lomb, Valeant Pharmaceuticals is acquiring an established eye care business as part of its healthcare holdings — the acquisition is valued at about US$8.7 billion including debt repayment.

Key takeaways are: the deal value is about US$8.7 billion (around $9 billion); Valeant will pay roughly US$4.5 billion to the investor group led by Warburg Pincus and about US$4.2 billion will go to repaying Bausch & Lomb's debt; and the transaction brings the eye care company under Valeant's ownership.